Welcome to our dedicated page for NYMOX PHARM news (Ticker: $NYMXF), a resource for investors and traders seeking the latest updates and insights on NYMOX PHARM stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect NYMOX PHARM's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of NYMOX PHARM's position in the market.
Rhea-AI Summary
Nymox Pharmaceutical (NYMXF) announces the end of Bahamas litigation with a court order in their favor, awarding costs and damages. CEO Dr. Paul Averback highlights the victory and commitment to shareholders. The company progresses with Nymozarfex drug treatments for prostate issues.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.53%
Tags
-
Rhea-AI Summary
Nymox Pharmaceutical Corporation (NYMXF) anticipates a positive year ahead after making significant advancements in the review process for their Nymozarfex drug for BPH and low-grade prostate cancer. The company has also undergone management changes and is committed to keeping shareholders informed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
41.51%
Tags
-
Rhea-AI Summary
Nymox Pharmaceutical Corporation (NYMXF) has obtained a preliminary injunction against certain individuals and is taking legal action against them for various wrongdoings. The company is confident in its position and continues to be supported by the majority of its shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Nymox Pharmaceutical Corporation (NYMXF) has filed a lawsuit against AscellaHealth, LLC in the California Superior Court, Orange County, alleging unlawful means in repeated attempts to gain control of Nymox for its own advantage. Nymox is seeking $250 million in compensatory and punitive damages.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.38%
Tags
-
Rhea-AI Summary
Nymox Pharmaceutical Corporation (NYMXF) files lawsuit against AscellaHealth, LLC for alleged illegal corporate espionage and attempts to gain control of the company. Nymox seeks $250 million in compensatory and punitive damages for the unlawful conduct.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.94%
Tags
-
Rhea-AI Summary
Nymox Pharmaceutical Corporation has announced that the Bahamian Court has suspended the Ex Parte Order obtained by activist shareholders. The court accepted Nymox's arguments and will now proceed to formally set aside the order. Nymox will also seek payment of legal costs and damages from the shareholders. For more information, contact info@nymox.com or 800-936-9669.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.24%
Tags
Rhea-AI Summary
Nymox Pharmaceutical Corporation has obtained a court order in California against ex-employees and agents Lanham, Riley, and Cutler, as well as their Nevada company. The order prohibits the defendants from using or disclosing Nymox privileged information and requires them to return all Nymox material to the company. This is a positive step in Nymox's efforts to protect its shareholders from attempts to steal the company's assets. Nymox urges shareholders to contact them if they receive communications containing privileged information.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.24%
Tags
-
Rhea-AI Summary
Nymox Pharmaceutical Corporation warns shareholders about an unauthorized shareholder meeting organized by former executives. The company accuses them of stealing proprietary shareholder information and violating non-disclosure agreements. Nymox has filed criminal complaints and taken legal actions to protect shareholders. The board has received support from the majority of voting shareholders. Former General Counsel Mr. Lanham is accused of embezzlement and fraudulent actions. Lanham, ex-CFO 3-Month Riley, and former board member Cutler failed to disclose their relationship with a separate entity and approached Nymox shareholders for investment in that entity. Lanham is also accused of offering Nymox stock as a kickback. Lanham and Riley were terminated after their kick-back scheme was uncovered. Nymox is confident that the unauthorized shareholder meeting will be set aside.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
-
Rhea-AI Summary
Nymox Pharmaceutical Corporation warns shareholders of an unauthorized shareholder meeting orchestrated by former executives involved in theft of confidential information. The company has taken legal action and filed criminal complaints to protect shareholders. Former General Counsel Mr. Lanham is accused of embezzlement and fraudulent actions. Ex-CFO 3-Month Riley and former board member Cutler failed to disclose their relationship with a separate entity, breaching their duties to Nymox shareholders. Lanham and Riley are accused of offering Nymox stock as a kickback for investing in their separate company. The company is confident that the unauthorized shareholder meeting will be set aside.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20%
Tags
Rhea-AI Summary
Nymox Pharmaceutical Corporation responds to unauthorized shareholder meeting. Company warns shareholders of false and manipulative behavior. Legal actions taken to protect shareholders. Former General Counsel and ex-CFO involved in fraudulent activities. Nymox confident that actions will be set aside. Stock price has improved since termination of individuals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
NYMOX PHARM CORP
OTC:NYMXF
NYMXF Rankings
NYMXF Stock Data
33.86M
53.09M
42.05%
0.05%
2.23%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
Nassau
About NYMXF
nymox pharmaceutical corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population. its lead drug candidate is fexapotide triflutate (nx-1207) that has completed phase iii clinical trials for the treatment of benign prostatic hyperplasia; and is in phase ii clinical trial for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. the company also develops and markets nicalert and tobacalert test strips that use urine or saliva to detect use of tobacco products. in addition, it offers alzheimalert, a proprietary urine assay that aids physicians in the diagnosis of alzheimer's disease. the company operates in canada, the united states, europe, and internationally. nymox pharmaceutical corporation was founded in 1989 and is headquartered in nassau, bahamas.